RxDoctor Payments Data

Rochelle Elayda

Family · Summerville, SCNPI 1336649953

Payments from drug & device makers

$5,361in general payments, 2019–2025

Across 288 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$804
  • AbbVie$521
  • Lilly USA, LLC$411
  • Pfizer$307
  • GSK$292
  • Sanofi-aventis U.S. LLC$280
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,361 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,604
Medicare patients
228
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$64,636
FarxigaDapagliflozin Propanediol62$64,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$55,937
JardianceEmpagliflozin51$50,487
VraylarCariprazine Hcl25$39,991
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$35,627
EliquisApixaban42$34,261
RybelsusSemaglutide22$30,758
TrulicityDulaglutide20$28,953
RexultiBrexpiprazole11$27,651
MounjaroTirzepatide29$27,523
JanuviaSitagliptin Phosphate29$26,552
MyrbetriqMirabegron23$23,586
LinzessLinaclotide20$18,389
EntrestoSacubitril/Valsartan11$11,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$804$105,847119 claims
Novo NordiskOzempic, Rybelsus$208$95,39362 claims
GSKTrelegy Ellipta, Breo Ellipta$292$61,03969 claims
AbbVieVraylar, Linzess, Synthroid$521$59,45760 claims
Lilly USA, LLCTrulicity, Mounjaro$411$56,47649 claims
Boehringer IngelheimJardiance$116$50,48751 claims
PfizerEliquis$307$34,26142 claims
Otsuka America Pharmaceutical, Inc.Rexulti$109$27,65111 claims
MerckJanuvia$56$26,55229 claims
Sumitomo Pharma America, Inc.Gemtesa$140$7,28715 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$7,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →